Unknown

Dataset Information

Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases.


ABSTRACT: Over the last decades, antiplatelet agents, mainly aspirin and P2Y12 receptor antagonists, have significantly reduced morbidity and mortality associated with arterial thrombosis. Their pharmacological characteristics, including pharmacokinetic/pharmacodynamics profiles, have been extensively studied, and a significant number of clinical trials assessing their efficacy and safety in various clinical settings have established antithrombotic efficacy. Notwithstanding, antiplatelet agents carry an inherent risk of bleeding. Given that bleeding is associated with adverse cardiovascular outcomes and mortality, there is an unmet clinical need to develop novel antiplatelet therapies that inhibit thrombosis while maintaining hemostasis. In this review, we present the currently available antiplatele

SUBMITTER: Jourdi G 

PROVIDER: S-EPMC8658271 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature